Freezing of Gait in Parkinsonism and its Potential Drug Treatment

Freezing of gait (FOG) is a heterogeneous symptom. Studies of treatment for FOG are scarce. Levodopa and monoamine oxidase inhibitors (rasagiline and selegiline) have shown effective improvement for FOG. Other drugs, such as L-threo-3, 4-dihydroxyphenylserine, amantadine, and botulinum toxin have ex...

Full description

Saved in:
Bibliographic Details
Published in:Current neuropharmacology 2016-05, Vol.14 (4), p.302-306
Main Authors: Zhang, Li-Li, Canning, S Duff, Wang, Xiao-Ping
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Amantadine - therapeutic use
Antiparkinson Agents - therapeutic use
Botulinum Toxins - therapeutic use
Droxidopa - therapeutic use
Gait Disorders, Neurologic - drug therapy
Gait Disorders, Neurologic - etiology
Humans
Indans - therapeutic use
Levodopa - therapeutic use
Methylphenidate - therapeutic use
Middle Aged
Monoamine Oxidase Inhibitors - therapeutic use
Parkinsonian Disorders - complications
Selegiline - therapeutic use
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Freezing of gait (FOG) is a heterogeneous symptom. Studies of treatment for FOG are scarce. Levodopa and monoamine oxidase inhibitors (rasagiline and selegiline) have shown effective improvement for FOG. Other drugs, such as L-threo-3, 4-dihydroxyphenylserine, amantadine, and botulinum toxin have exhibited some beneficial effects. The present review summarizes the potential drug treatment for FOG in Parkinsonism.
ISSN:1570-159X
1875-6190
DOI:10.2174/1570159X14666151201190040